Market Place
Sourcing Support
Kymera Therapeutics to Participate in Nov Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Kymera pivots to immunology, seeks partners for cancer assets
04 Nov 2024 //
FIERCE BIOTECH
Kymera Therapeutics Reports Q3 2024 Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Reports Q3 2024 Financial Results
31 Oct 2024 //
GLOBENEWSWIRE
Kymera Doses First Participant In KT-621 Phase 1 Trial
24 Oct 2024 //
GLOBENEWSWIRE
Kymera Announces Three Presentations at EORTC-NCI-AACR
23 Oct 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Q3 2024 Financial Results on October 31
23 Oct 2024 //
GLOBENEWSWIRE
Kymera Announces FDA Clearance Of IND For KT-621
09 Oct 2024 //
GLOBENEWSWIRE
Kymera Presents KT-621 Preclinical Data At EADV Congress
25 Sep 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Closes $225M Public Offering With Full Option Exercise
21 Aug 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Proposed Public Offering
19 Aug 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
19 Aug 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Reports Q2 2024 Results And Provides Business Update
07 Aug 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
31 Jul 2024 //
GLOBENEWSWIRE
Kymera Therapeutics To Present At UBS Protein Degradation Day
09 Jul 2024 //
GLOBENEWSWIRE
Kymera Announces Expansion Of KT-474 HS And AD Phase 2 Studies
08 Jul 2024 //
GLOBENEWSWIRE
Kymera Presents KT-333 Phase 1 Data At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
Kymera`s MDM2 Degrader KT-253 Shows New Phase 1 Data At ASCO
01 Jun 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
29 May 2024 //
GLOBENEWSWIRE
Kymera Kt-253 Mdm2 New Data: Phase 1 Trial At Asco Meeting
23 May 2024 //
GLOBENEWSWIRE
Kymera Presents Preclinical STAT6 Degrader KT-621 Data At ATS
22 May 2024 //
GLOBENEWSWIRE
Kymera To Present KT-333 STAT3 Degrader Data At EHA Meeting
14 May 2024 //
GLOBENEWSWIRE
NEOsphere, Kymera Collaborate on Novel Molecular Glue Target Discovery
14 May 2024 //
BIOTECHNEWSWIRE
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
08 May 2024 //
GLOBENEWSWIRE
Kymera Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
25 Apr 2024 //
GLOBENEWSWIRE
Kymera Announces Scientific Presentations at the AACR 2024 Annual Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 Programs
08 Mar 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
28 Feb 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Fourth Quarter & Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Kymera to Report Fourth Quarter and Full Year 2023 Financial Results
15 Feb 2024 //
GLOBENEWSWIRE
Kymera to Present in Fireside Chat at the Guggenheim Healthcare Conference
31 Jan 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering
09 Jan 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Outlines Key 2024 Objectives
09 Jan 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
05 Jan 2024 //
GLOBENEWSWIRE
Kymera doubles down on protein degraders for immunology
04 Jan 2024 //
ENDPTS
R&D Day Highlights Kymera™s Immunology Strategy and Emerging Pipeline
04 Jan 2024 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Proposed Public Offering
04 Jan 2024 //
GLOBENEWSWIRE
Kymera to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
13 Dec 2023 //
GLOBENEWSWIRE
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Trial
10 Dec 2023 //
GLOBENEWSWIRE
Kymera Announces First Patient Dosed in Ph 2 Atopic Dermatitis Trial of KT-474
07 Dec 2023 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474
13 Nov 2023 //
GLOBENEWSWIRE
Kymera Therapeutics Announces Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Kymera Therapeutics to Present Clinical Data from the Phase 1 Trial of KT-333
02 Nov 2023 //
GLOBENEWSWIRE
Kymera cuts lymphoma med that performed as expected in phase 1
02 Nov 2023 //
FIERCE BIOTECH
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Kymera Announces First Patient Dosed in Phase 2 Trial of KT-474
27 Oct 2023 //
GLOBENEWSWIRE
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
26 Oct 2023 //
GLOBENEWSWIRE
Kymera Therapeutics Presents Data Demonstrating Activity of MDM2 Degraders
16 Oct 2023 //
GLOBENEWSWIRE
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333
18 Sep 2023 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
28 Aug 2023 //
GLOBENEWSWIRE
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
27 Jul 2023 //
GLOBENEWSWIRE
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253
22 Jun 2023 //
GLOBENEWSWIRE
Kymera`s STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Safety
14 Jun 2023 //
PRESS RELEASE
Kymera`s STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown
14 Jun 2023 //
GLOBENEWSWIRE
Kymera Announces Updated Data from the Phase 1 Trials of STAT3 Degrader KT-333
09 Jun 2023 //
PRESS RELEASE
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253
09 Jun 2023 //
GLOBENEWSWIRE
Kymera Therapeutics to Participate in Upcoming June Investor Conference
01 Jun 2023 //
GLOBENEWSWIRE
